NEW YORK (GenomeWeb News) – Sigma-Aldrich today said that it has signed an agreement to market Axiogenesis' mouse-induced pluripotent stem cell-derived cardiomyocytes and smooth muscle cells for preclinical cardiotoxicity screening.

The Sigma Life Science business of Sigma-Aldrich will offer the products as ready-to-order cells, application-specific kits, and custom services. Financial and other terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.